A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women

Summary

The purpose of this study is to evaluate the tolerability of two different formulations of blosozumab in women who have reached menopause. This study will last approximately 12 weeks for each participant, not including screening. Screening is required within 28 days prior to starting the study.

Timeline

Start

2015-01

Primary completion

2015-03

Completion

2015-03

Outcome

Outcome not reported

Stopped: “Protocol stopping criteria (safety) were met.”

Drugs

Indications